このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Acute Effect of Immersive VR Technology on Postural Control and Reaction Time in Young Adults

2026年7月11日 更新者:Maciej Kochman、University of Rzeszow

Acute Effect of Immersive VR Technology on Postural Control and Reaction Time in Young Adults: a Randomized Controlled Trial

This study investigates the acute effects of short-term immersive virtual reality (VR) exposure on sensory organization and reaction time in young adults aged 18-25 years. It is designed as a randomized controlled trial.

Participants are eligible if they provide written informed consent, complete all study questionnaires, are aged 18-25 years, are able to maintain an upright standing posture, have non-professional athletic status, have no neurological or psychiatric disorders, use a phone or computer for at least 1 hour per day, and do not take medication affecting the nervous system. Exclusion criteria include age outside the 18-25 range, pregnancy, disability, metal implants, epilepsy, inability to provide consent, frequent migraines, balance disorders, recent surgery or injury (within 6 months), uncorrected visual impairment, skin conditions or allergies preventing device use, acute illness on the day of testing, shift work causing circadian rhythm disruption, prior regular VR use, claustrophobia or anxiety related to enclosed spaces or simulated movement, and intensive physical activity within 24 hours before testing.

Eligible participants are randomly allocated in a 1:1 ratio using sequentially numbered, sealed, opaque envelopes to either a VR intervention group or a control group.

All participants are assessed at baseline and after a 20-minute interval. In the VR group, post-assessment is performed immediately after VR exposure, while in the control group it follows a matched resting period. All measurements are conducted by a single trained examiner at a similar time of day using a standardized protocol. Anthropometric measurements (height and body mass) are obtained barefoot using a medical scale (Charder MS4971, Taiwan), and body mass index (BMI) is calculated.

Postural control and reaction time are assessed using computerized dynamic posturography with the NeuroCom Balance Manager system. Two standardized protocols are used: the Sensory Organization Test (SOT) and the Limits of Stability (LOS). The SOT evaluates the integration of somatosensory, visual, and vestibular inputs for postural control across six sensory conditions involving variations in platform and visual stability. The LOS assesses voluntary control of the center of gravity toward visual targets without loss of balance, providing measures of movement accuracy and reaction time from movement initiation to target acquisition.

The primary outcome is the composite SOT score. Secondary outcomes include SOM, VIS, VEST, and PREF parameters derived from the SOT, as well as reaction time measured in the LOS protocol.

The experimental group undergoes a 20-minute VR intervention using the HTC VIVE Cosmos. The intervention consists of a gamified motor coordination task ("Adventure Climb") requiring continuous postural adjustments, rapid visuomotor responses, and whole-body movement coordination in a standing position. The task is designed to stimulate visual-motor integration and dynamic balance control. The control group remains at rest for the same duration and does not receive any active intervention, allowing isolation of the effects of VR exposure. Due to the nature of the intervention, blinding of participants, assessors, and intervention providers is not feasible.

After the intervention or rest period, all participants repeat the SOT and LOS assessments under identical conditions to evaluate the acute effects of VR exposure on postural control and reaction time.

調査の概要

詳細な説明

This study evaluates the acute effects of short-term immersive virtual reality (VR) exposure on sensory organization and reaction time in young adults aged 18-25 years. It is designed as a randomized controlled trial.

Participants are eligible if they provide written informed consent and complete all study questionnaires, are aged between 18 and 25 years, are able to maintain an upright standing posture, have non-professional athletic status, have no diagnosed neurological or psychiatric disorders, use a phone or computer for at least 1 hour per day, and do not use medication affecting the nervous system. Exclusion criteria include age under 18 or over 25 years, pregnancy, disability, metal implants, epilepsy, inability to provide informed consent, frequent migraines, balance disorders, surgery or injury within the previous 6 months, uncorrected visual impairment, skin conditions or allergies preventing device use, acute illness on the day of testing, shift work causing circadian rhythm disruption, prior regular use of VR technology, claustrophobia or anxiety related to enclosed spaces or simulated movement, and intensive physical activity within 24 hours prior to testing.

Eligible participants are randomly allocated in a 1:1 ratio using sequentially numbered, sealed, opaque envelopes to either a VR intervention group or a control group.

All participants are assessed at baseline and again after a 20-minute interval. In the VR group, the post-assessment is conducted immediately after VR exposure, whereas in the control group it follows a matched resting period. All measurements are performed by a single trained examiner at a similar time of day using a standardized protocol. Anthropometric data, including height and body mass, are collected barefoot using a medical scale (Charder MS4971, Taiwan), and body mass index (BMI) is calculated.

Postural control and reaction time are evaluated using computerized dynamic posturography with the NeuroCom Balance Manager system, applying two standardized protocols: the Sensory Organization Test (SOT) and the Limits of Stability (LOS). The SOT assesses integration of somatosensory, visual, and vestibular inputs for postural control through six conditions (fixed or sway-referenced platform and vision), each repeated three times, conducted according to manufacturer guidelines with participants standing in a safety harness and standardized foot positioning aligned to the platform's axis of rotation. The LOS protocol evaluates voluntary control of the center of gravity toward visual targets without losing balance, providing measures of movement accuracy and reaction time from initiation of weight shift to target acquisition.

The primary outcome is the composite SOT score, while secondary outcomes include SOM, VIS, VEST, and PREF parameters derived from the SOT, as well as reaction time measured in the LOS protocol.

The experimental group completes a 20-minute VR-based intervention using the HTC VIVE Cosmos, consisting of a gamified motor coordination task ("Adventure Climb") that requires continuous postural adjustments, rapid visuomotor responses, and whole-body movement coordination in a standing position. The task is designed to stimulate visual-motor integration and dynamic balance control. The control group remains at rest for the same duration and does not receive any active intervention, allowing isolation of the effects of immersive VR exposure without additional sensory or motor stimulation. Due to the nature of the intervention, blinding of participants, assessors, and the intervention provider is not feasible.

After the intervention or rest period, all participants repeat the SOT and LOS assessments under identical conditions, enabling comparison of baseline and post-condition performance and evaluation of the acute effects of VR exposure on postural control and reaction time.

研究の種類

介入

入学 (実際)

81

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Rzeszów、ポーランド、35-328
        • University of Rzeszow

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人

健康ボランティアの受け入れ

はい

説明

Inclusion Criteria:

  • written informed consent and complete questionnaire completion;
  • age between 18 and 25 years;
  • ability to maintain upright standing posture;
  • non-professional athletic status;
  • no neurological or psychiatric disorders;
  • regular use of a phone or computer for at least 1 hour per day;
  • no medication affecting the nervous system.

Exclusion Criteria:

  • age <18 or >25 years;
  • pregnancy;
  • disability;
  • metal implants;
  • epilepsy;
  • lack of informed consent;
  • frequent migraines;
  • balance disorders;
  • surgery or injury within the previous 6 months;
  • uncorrected visual impairment;
  • skin conditions or allergies preventing device use;
  • acute illness on the day of testing;
  • shift work causing circadian rhythm disruption;
  • prior regular use of VR technology;
  • claustrophobia or anxiety related to enclosed spaces or simulated movement; and
  • intensive physical activity within 24 hours prior to testing.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:他の
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:VR intervention
A 20-minute VR-based intervention using the HTC VIVE Cosmos as a gamified motor coordination task ("Adventure Climb") requiring continuous postural adjustments, rapid visuomotor responses, and whole-body movement coordination in a standing position. The task is designed to stimulate visual-motor integration and dynamic balance control
A 20-minute VR-based intervention using the HTC VIVE Cosmos as a gamified motor coordination task ("Adventure Climb") requiring continuous postural adjustments, rapid visuomotor responses, and whole-body movement coordination in a standing position. The task is designed to stimulate visual-motor integration and dynamic balance control
介入なし:Control
Remaining at rest during the corresponding period

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Composite Score (CS) (%)
時間枠:up to 10 weeks
Composite score (CS) is assessed using the NeuroCom Balance Manager system during the Sensory Organization Test (SOT). The score represents overall postural stability across all SOT conditions. Higher scores indicate better postural stability.
up to 10 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Somatosensory Index (SOM) (%)
時間枠:up to 10 weeks
Somatosensory (SOM) index is assessed using the NeuroCom Balance Manager system during the SOT. It reflects the participant's ability to use somatosensory input for postural control. Higher values indicate better somatosensory reliance.
up to 10 weeks
Visual Index (VIS) (%)
時間枠:up to 10 weeks
Visual (VIS) index is assessed using the NeuroCom Balance Manager system during the SOT. It reflects the ability to use visual input for postural control. Higher values indicate better visual reliance for balance.
up to 10 weeks
Vestibular Index (VEST) (%)
時間枠:up to 10 weeks
Vestibular (VEST) index is assessed using the NeuroCom Balance Manager system during the SOT. It reflects the ability to use vestibular input for postural control. Higher values indicate better vestibular reliance.
up to 10 weeks
Visual Preference Index (PREF) (%)
時間枠:up to 10 weeks
Visual preference (PREF) index is assessed using the NeuroCom Balance Manager system during the SOT. It reflects reliance on visual information even when it may be inaccurate. Higher values indicate greater visual preference.
up to 10 weeks
Reaction Time (RT) (s)
時間枠:up to 10 weeks
Reaction time is assessed using the NeuroCom Balance Manager system during the Limits of Stability (LOS) test. It represents the time from initiation of weight shift to movement onset toward the target. Lower values indicate faster reaction time.
up to 10 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年1月22日

一次修了 (実際)

2026年3月31日

研究の完了 (実際)

2026年3月31日

試験登録日

最初に提出

2026年7月6日

QC基準を満たした最初の提出物

2026年7月11日

最初の投稿 (実際)

2026年7月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年7月16日

QC基準を満たした最後の更新が送信されました

2026年7月11日

最終確認日

2026年7月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する